Allogene insider vests 9,586 shares (Form 144)

Allogene Therapeutics submitted a Form 144 reporting the vesting of 9,586 shares of Common Stock from a restricted stock unit award.

Rhea-AI Filing Summary

Allogene Therapeutics submitted a Form 144 reporting the vesting of 9,586 shares of Common Stock from a restricted stock unit award. The vesting date shown is 04/20/2026 and the Form 144 filing line shows 04/21/2026.

Insights

Corporate Governance Analyst

Routine insider compensation event: RSU vesting and sale notice.

The filing line documents the vesting of 9,586 restricted stock units associated with an issuer equity compensation plan, and a Form 144 entry that typically notifies the market of an intended sale by the recipient. The broker/dealer listed is Morgan Stanley Smith Barney LLC.

There is no pricing, proceeds, or explicit sale execution information in the excerpt; timing and cash‑flow treatment are not shown in the provided lines. Subsequent filings or the Form 4 would show executed trades and post‑transaction holdings.

Key Figures

Vested shares: 9,586 shares Form 144 line date: 04/21/2026 Vesting date: 04/20/2026

3 metrics

Vested shares 9,586 shares vesting of restricted stock unit award on 04/20/2026

Form 144 line date 04/21/2026 date shown on the filing line

Vesting date 04/20/2026 restricted stock unit award vesting date

Key Terms

Restricted stock unit (RSU), Form 144, Broker/dealer

3 terms

Restricted stock unit (RSU) financial

"Vesting of restricted stock unit award on 04/20/2026"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Broker/dealer financial

"Morgan Stanley Smith Barney LLC 1 New York Plaza"

A broker/dealer is a firm or person that both carries out trades for clients (broker) and buys or sells securities from its own inventory (dealer). Think of it as a shop that can take customer orders and also sell items off its own shelves. Investors care because broker/dealers connect buyers and sellers, influence the price and speed of trades, hold securities or cash for short periods, and can create conflicts of interest that affect trade cost and reliability.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Allogene's Form 144 filing for ALLO mean?

It notifies the SEC of an intended sale following an equity compensation event. The entry records the vesting of 9,586 shares on 04/20/2026 and a Form 144 line dated 04/21/2026, typically required before public resale by affiliates.

Does the Form 144 confirm the shares were sold for ALLO?

No. The Form 144 line indicates a proposed sale notice after vesting of 9,586 shares. It does not confirm execution, sale price, or proceeds. A subsequent Form 4 or broker report would show completed trades and prices.

Who is the broker listed on the Form 144 for ALLO?

The broker/dealer listed is Morgan Stanley Smith Barney LLC at 1 New York Plaza. The form line names the executing broker associated with the proposed resale; it does not indicate trade execution or timing beyond the filing date.

Are these shares part of Allogene's equity compensation plan?

Yes. The excerpt states the securities were granted as part of an issuer equity compensation plan and shows the vesting of restricted stock unit awards on 04/20/2026, resulting in the reported 9,586 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 08:22 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001835208
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Allogene Therapeutics, Inc.
SEC File Number	001-38693
Address of Issuer	210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	Yoshiyama Annie
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9586	22103.14	243777920	04/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	04/20/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.			9586	04/20/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	04/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Annie Yoshiyama
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)